ライフサイエンスコーパス: valacyclovir

1 iation of effective antiviral treatment with valacyclovir.

2 doses of 100 mg of pritelivir with 500 mg of valacyclovir.

3 l-3-HPG exhibited comparable permeability to valacyclovir.

4 atients with herpes zoster were treated with valacyclovir.

5 ing while receiving pritelivir compared with valacyclovir.

6 ravenous acyclovir, she was switched to oral valacyclovir.

7 rred after discontinuation of treatment with valacyclovir.

8 x virus reactivation (n = 932); acyclovir or valacyclovir 1 year (n = 1117); or acyclovir/valacyclovi

9 acyclovir (500 mg twice daily), or high-dose valacyclovir (1 g twice daily) in this 18-week trial.

10 14 of the susceptible partners who received valacyclovir (1.9 percent), as compared with 27 (3.6 per

11 the safety and efficacy of an oral dosage of valacyclovir, 1 g TID versus 2 g TID, for the treatment

12 Oral valacyclovir, 1 g twice daily, was administered to 65 ou

13 Eight patients received oral valacyclovir 2 g tid (Valtrex, GlaxoSmithKline) and one

14 r 1 year after initial treatment with 1 g of valacyclovir 3 times daily for 1 week in a prospective,

15 A dosage of 1 g of valacyclovir 3 times per day (TID) for 7 days has alread

16 mg as a single dose), placebo for 3 days, or valacyclovir (500 mg twice daily for 3 days).

17 To determine the efficacy and safety of valacyclovir (500 mg twice daily) for the suppression of

18 mized 1:1:1 to 12 weeks of placebo, low-dose valacyclovir (500 mg twice daily), or high-dose valacycl

19 1200 mg; HR, 1.72; P = .007), and 113.9 with valacyclovir (500 mg twice daily; HR, 1.42; P = .077), i

20 yclovir daily or with a combination of daily valacyclovir (500 mg) plus twice-daily doses of aspirin

21 ex virus type 2 (HSV-2)-suppressive therapy (valacyclovir, 500 mg twice daily, or placebo for 8 weeks

22 Treatment of infected mice with valacyclovir, a potent inhibitor of HSV-1 replication, p

23 articipants with genital HSV-2 received oral valacyclovir, acyclovir, and matching placebo in random

24 aneous specimens obtained during placebo and valacyclovir administration, respectively (P<.001).

25 Treatment with valacyclovir also decreased the rates of CMV viremia and

26 ession of viral replication is not complete, valacyclovir and acyclovir are highly effective in suppr

27 tity of HSV were detected by PCR between the valacyclovir and acyclovir arms.

28 The efficacy of valacyclovir and acyclovir on genital herpes simplex vir

29 Many of the antivirals discussed, including valacyclovir and cidofovir, have not yet been studied in

30 ; however, newer antiviral agents, including valacyclovir and famciclovir, have expanded therapeutic

31 significant difference was found between the valacyclovir and placebo groups.

32 95% confidence interval [CI], 0.01-0.07] for valacyclovir and RR, 0.05 [95% CI, 0.03-0.10] for acyclo

33 r) and PCR (RR, 0.18 [95% CI, 0.12-0.26] for valacyclovir and RR, 0.20 [95% CI, 0.15-0.28] for acyclo

34 elation was found between HSV-1 shedding and valacyclovir and valacyclovir with aspirin treatment.

35 t BPHL may be an important enzyme activating valacyclovir and valganciclovir in humans and an importa

36 ted significant hydrolytic activity for both valacyclovir and valganciclovir with specificity constan

37 specificity of a novel activating enzyme for valacyclovir and valganciclovir.

38 led by high-dose prophylaxis with acyclovir, valacyclovir, and famciclovir.

39 (10) copies/mL; 95% CI, -.73 to -.30) in the valacyclovir arm than the placebo arm.

40 V-1 level was significantly lower during the valacyclovir arm, compared with the placebo arm (-0.26 l

41 s with newly diagnosed ARN treated with oral valacyclovir as the sole antiviral agent.

42 To report the outcome of oral valacyclovir as the sole antiviral therapy for patients

43 Treatment with oral valacyclovir as the sole antiviral therapy resulted in c

44 SV-2-infected (source) partners who received valacyclovir, as compared with 10.8 percent of the days

45 4 of 743 susceptible partners who were given valacyclovir, as compared with 16 of 741 who were given

46 ls/ microL were randomized to receive either valacyclovir at 500 mg twice daily or placebo for 8 week

47 The impact of valacyclovir (both groups combined) on each outcome was

48 rials of topical trifluorothymidine and oral valacyclovir but resolved completely with the applicatio

49 AdV-tk plus valacyclovir can be safely delivered with surgery and ac

50 Controlled trials suggest that acyclovir/valacyclovir can provide significant clinical benefits w

51 was not reduced by treatment with 500 mg of valacyclovir daily or with a combination of daily valacy

52 Valacyclovir did not decrease systemic immune activation

53 Valacyclovir did not reduce the number of cervical CD4(+

54 dies suggest that standard-dose acyclovir or valacyclovir does not select for HIV-1 resistance.

55 Valacyclovir enhances acyclovir bioavailability compared

56 Valacyclovir exhibits better oral absorption and higher,

57 n and efficacy of the newly developed agents valacyclovir, famciclovir, cidofovir, oral and intraocul

58 ive pritelivir [corrected] and 46 to receive valacyclovir first when the US Food and Drug Administrat

59 valacyclovir 1 year (n = 1117); or acyclovir/valacyclovir for at least 1 year or longer if patients r

60 the United States taking daily acyclovir or valacyclovir for between 8 weeks and 24 months.

61 : To compare the efficacy of pritelivir with valacyclovir for suppression of genital HSV-2 infection.

62 cal antiviral, sorivudine, as an adjuvant to valacyclovir for the treatment of acute herpes zoster.

63 placebo group (median, 59 days) than in the valacyclovir group (median, >180 days).

64 days in the pritelivir group vs 3.9% in the valacyclovir group (RR, 0.40; 95% CI, 0.17-0.96; P = .04

65 er of EBV-infected B cells over time for the valacyclovir group versus the control group approached s

66 livir group and 69.2% of participants in the valacyclovir group.

67 s (P = 0.62 and P = 0.92 for the control and valacyclovir groups, respectively).

68 cted B cells decreased in subjects receiving valacyclovir (half-life of 11 months; P = 0.02) but not

69 gnificantly higher among patients exposed to valacyclovir (hazard ratio, 3.29 [95% confidence interva

70 fety monitoring data from clinical trials of valacyclovir, involving over 3000 immunocompetent and im

71 Prophylactic treatment with valacyclovir is a safe and effective way to prevent CMV

72 The increased bioavailability of valacyclovir is attributed to carrier-mediated intestina

73 tion of extending the benefits of acyclovir, valacyclovir is now being explored in a number of HSV-re

74 Valacyclovir is the 5'-valyl ester prodrug of acyclovir,

75 16 percent among seronegative recipients of valacyclovir; it was 6 percent among seropositive placeb

76 Safety profiles of valacyclovir (</=1000 mg/day), acyclovir (800 mg/day), a

77 to the tongue appeared to occur even during valacyclovir-mediated suppression of EBV replication, su

78 ipient or donor) to 3-month prophylaxis with valacyclovir (n=34) or pre-emptive valganciclovir for si

79 on of the effect of the antiviral medication valacyclovir on the symptoms of outpatients with persist

80 d group 3 (n = 16) received a dose of 500 mg valacyclovir once daily and 350 mg aspirin twice daily f

81 andomly assigned to receive either 500 mg of valacyclovir once daily or placebo for eight months.

82 , group 2 (n = 15) received a dose of 500 mg valacyclovir once daily, and group 3 (n = 16) received a

83 can be achieved after administration of oral valacyclovir or intravenous acyclovir.

84 Valacyclovir or matched placebo was given (2 g twice on

85 ed, double-blind trial of twice daily 500 mg valacyclovir or placebo beginning at 34 weeks gestation

86 e randomly assigned to receive either 2 g of valacyclovir or placebo orally four times daily for 90 d

87 costeroids alone, the addition of acyclovir, valacyclovir, or famcyclovir to oral corticosteroids for

88 Thirty participants received 1 g of valacyclovir orally each day for 2 months in a randomize

89 In conclusion, acyclovir/valacyclovir prophylaxis given for 1 year led to a persi

90 In conclusion, compared with valacyclovir prophylaxis, pre-emptive valganciclovir the

91 with 5 years' postmarketing experience with valacyclovir provides evidence of favorable safety and e

92 reatment of HLP and of EBV replication, with valacyclovir, provides new insight into the mechanisms o

93 mong placebo recipients and 26 percent among valacyclovir recipients (P=0.001).

94 of genital herpes at 6 months was 65% among valacyclovir recipients versus 26% among placebo recipie

95 recipients and 1 percent among seropositive valacyclovir recipients.

96 among placebo recipients and 3 percent among valacyclovir recipients.

97 Valacyclovir reduced breast milk HIV-1 RNA detection at

98 Treatment with valacyclovir reduced the incidence or delayed the onset

99 Although valacyclovir reduced the latent viral DNA load better in

100 Daily suppressive therapy with valacyclovir reduces risk of sexual transmission of herp

101 Valacyclovir reduces the frequency of EBV-infected B cel

102 Valacyclovir resulted in a 0.16 (95% confidence interval

103 l HSV-2, the use of pritelivir compared with valacyclovir resulted in a lower percentage of swabs wit

104 for pritelivir and 1.6 per person-month for valacyclovir (RR, 0.80; 95% CI, 0.52 to 1.22; P = .29).

105 Valacyclovir significantly decreased early breast milk a

106 Valacyclovir significantly reduces rectal and plasma HIV

107 Once-daily suppressive therapy with valacyclovir significantly reduces the risk of transmiss

108 In time-updated analyses, valacyclovir significantly suppressed the virus load in

109 with significant hydrolytic activity toward valacyclovir, the 5'-glycyl ester of acyclovir, and the

110 vels that could facilitate transmission, and valacyclovir therapy decreases the prevalence of EBV in

111 Short-term valacyclovir therapy did not reverse HSV-2-associated al

112 erpes zoster were randomized to receive oral valacyclovir therapy for 7 days, either 1 g TID or 2 g T

113 The oral dosage schedule of 2 g of valacyclovir TID reaches acyclovir plasma levels similar

114 cterization of a human enzyme that activates valacyclovir to acyclovir.

115 replication were treated with high-dose oral valacyclovir to inhibit productive EBV replication.

116 n was characterized in subjects treated with valacyclovir to suppress EBV replication.

117 ivir treatment vs 3.7 log10 copies/mL during valacyclovir treatment (difference, -0.1; 95% CI, -0.6 t

118 ment compared with 5.3% (392 of 7453) during valacyclovir treatment (relative risk [RR], 0.42 [correc

119 Valacyclovir treatment completely abrogated EBV replicat

120 All patients began 7 days of valacyclovir treatment on day 3.

121 However, valacyclovir treatment resulted in significantly fewer p

122 inations and confusion were more common with valacyclovir treatment, but these events were not severe

123 -infected subjects before, during, and after valacyclovir treatment.

124 rned in normal tongue epithelial cells after valacyclovir treatment.

125 mozolomide was administered after completing valacyclovir treatment.

126 side derivatives acyclovir, famciclovir, and valacyclovir, treatment of mucocutaneous HSV is a practi

127 ere assigned to placebo (n = 51) or 0.5 g of valacyclovir twice daily (n = 50) for 1 year after initi

128 Suppressive treatment with 0.5 g of valacyclovir twice daily was not shown to prohibit recur

129 nal fluid) were randomized to receive either valacyclovir (VACV) 2 g thrice daily (n = 40) or placebo

130 We treated volunteers with either valacyclovir (valaciclovir) or no antiviral therapy for

131 suppressive therapy using ACV or its prodrug valacyclovir (valACV) reduced plasma HIV-1 viral load (V

132 r hours after intravitreal injection of HSV, valacyclovir was introduced into the drinking water of t

133 Valacyclovir was not associated with significant changes

134 Valacyclovir was safe and effective for the suppression

135 Valacyclovir was well tolerated; the incidence of advers

136 Thus, in this study, famciclovir and valacyclovir were equally effective in limiting the viru

137 fficacy for such infections, famciclovir and valacyclovir, were tested in a mouse eye model of HSV in

138 between HSV-1 shedding and valacyclovir and valacyclovir with aspirin treatment.

139 ontrolled trial that compared the effects of valacyclovir with those of acyclovir for CMV disease pre

140 ontrolled trial that compared the effects of valacyclovir with those of acyclovir.

141 ypothesized that prophylactic treatment with valacyclovir would reduce the risk of CMV disease.